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Introduction {#sec1}
============

Meiosis is a specialized cell division consisting of one round of DNA replication followed by two rounds of chromosome segregation. During meiosis I, homologous chromosomes must pair, synapse, and form crossovers to enable accurate segregation at the first meiotic division (MI). During the second meiotic division (MII), the paired sister chromatids segregate, resulting in the formation of haploid gametes ([@bib24]).

Crossing over is achieved through meiotic recombination, which is dependent on, and required for, accurate synapsis. Synapsis is achieved by the formation of the synaptonemal complex (SC), whose assembly and status defines the five sub-stages of prophase I. Meiotic recombination is initiated by the formation of programmed DNA double-strand breaks (DSBs) throughout the genome in early leptonema ([@bib7]; [@bib32], [@bib33], [@bib55], [@bib56]; [@bib57]). In the mouse, 200--300 DSBs are generated and processed through common intermediate repair steps to yield either non-crossover or crossover events ([@bib24]). While the majority of DSBs (∼90% in the mouse) repair as non-crossovers in zygonema and early pachynema, the crossovers that form during pachynema establish the inter-homolog tethers that allow for their correct segregation at MI ([@bib17]). Thus, the correct timing, frequency, and distribution of crossovers ensures that at least one crossover per pair is generated (the obligate crossover) ([@bib29]), that crossovers are maintained at the expense of non-crossovers (crossover homeostasis) ([@bib16]; [@bib43]), and that the formation of one crossover prevents the formation of nearby crossovers (interference) ([@bib30]). How these rules are enforced within the realm of DSB repair and shape crossover and non-crossover decisions remains unclear.

In the mouse, crossovers can form by at least two mechanisms. The class I (ZMM) pathway is responsible for the majority of crossovers and uses the DNA mismatch repair endonuclease MutLγ, a heterodimer of MLH1 and MLH3 ([@bib20]; [@bib40]). MLH1 and MLH3 co-localize along chromosome cores at a frequency of ∼23 foci at pachynema ([@bib5]), reflecting 90%--95% of the final crossover count in male meiosis ([@bib40]; [@bib66]). The distribution of MutLγ foci during pachynema in mouse spermatocytes is interference dependent and satisfies the requirement for the obligate crossover ([@bib13]). Loss of either component of MutLγ results in infertility due to the loss of most crossovers, leading to arrest before metaphase I in males and meiosis I non-disjunction in females ([@bib5]; [@bib20]; [@bib35]; [@bib40]). The remaining 5%--10% crossovers are generated by the class II MUS81-EME1-dependent pathway. These class II crossovers are interference independent, but cannot account for all of the class I-independent crossovers since the mutation of both *Mlh3* and *Mus81* leads to the persistence of 1--3 chiasmata ([@bib26]).

One of the major questions in mammalian meiosis concerns how crossovers are selected from the initial pool of 200--300 DSB repair intermediates. Initially, a subset (∼150) of these repair intermediates accrue the MutSγ heterodimer of MSH4 and MSH5 ([@bib21]; [@bib34]), an event called crossover licensing. Of these, only 23--26 MutSγ sites subsequently become loaded with MutLγ to form class I crossovers, while the remaining sites are repaired either through the class II crossover pathway or via the formation of non-crossovers ([@bib17]; [@bib26]; [@bib45]). The mechanism by which MutSγ becomes further selected by the accrual of MutLγ has been called crossover designation, leading to the idea that crossover homeostasis is imposed sequentially by the association of these pro-crossover MutS/MutL proteins ([@bib16]; [@bib28]; [@bib46]).

Recent studies have revealed a number of regulatory molecules that aid in crossover designation and that are essential for class I crossovers, including crossover site-associated-1 (COSA-1) in *Caenorhabditis elegans* ([@bib69]) and its mammalian ortholog cyclin N-terminal domain-containing-1 (CNTD1) ([@bib27]). Loss of COSA-1 in worms results in a failure to accumulate MSH-5 at DSB repair intermediates and the loss of all crossovers ([@bib69]). The loss of CNTD1 in the mouse results in similar meiotic failure characterized by persistently elevated early crossover factors through pachynema and failure to load crossover designation factors such as MutLγ, the crossover site-associated cyclin-dependent kinase-2 (CDK2), and the putative ubiquitin E3 ligase HEI10 ([@bib27]). In the present study, we sought to further elucidate the function of CNTD1 in driving crossover formation. We generated a dual epitope-tagged allele of *Cntd1* (*Cntd1* ^*FH*^ *)* to facilitate the tracking of CNTD1 protein in mouse spermatocytes and to enable the analysis of the CNTD1 interactome. We find that CNTD1 localizes to sites that are loaded with MutLγ, but surprisingly, the predominant form of CNTD1 in spermatocytes lacks the ability to interact with known meiotic CDKs or crossover factors. Instead, CNTD1 drives crossover designation and cell-cycle progression through distinct interactions with key regulatory complexes involved in facilitating the activity of MutLγ (namely replication factor C \[RFC\]) and those involved in modulating cell-cycle progression through the ubiquitylation of critical cell-cycle regulators (namely CDC34-containing SKP1-Cullin-Fbox \[SCF\] complex).

Results {#sec2}
=======

Epitope Tagging of CNTD1 to Create a *Cntd1*^*FLAG-HA*^ Allele Reveals a Short-Form CNTD1 {#sec2.1}
-----------------------------------------------------------------------------------------

We used CRISPR-Cas9 to generate a dual C-terminal FLAG-hemagglutinin (HA) epitope tagged allele ([Figure S2](#mmc1){ref-type="supplementary-material"}A), called *Cntd1* ^*FH*^. The dual tag was placed at the 3′ end of the protein, preceding the stop codon. *Cntd1* ^*FH/FH*^ male mice are almost indistinguishable from wild-type littermates ([Figure S1](#mmc1){ref-type="supplementary-material"}).

Annotation of the *Cntd1* genomic locus describes a 7-exon gene encoding a 334-amino acid protein with a predicted molecular weight of ∼40 kDa for the full-length, tagged form ([Figures 1](#fig1){ref-type="fig"} A and [S2](#mmc1){ref-type="supplementary-material"}A) (NCBI: NM_026562). Western blotting (WB) of whole testis extracts from *Cntd1* ^*+/+*^, *Cntd1* ^*FH/+*^, and *Cntd1* ^*FH/FH*^ adult matched littermates demonstrated the presence of the protein specifically in mice bearing the *Cntd1* ^*FH*^ allele, but revealed a smaller-than-expected band at ∼30 kDa, present only in the testis ([Figures 1](#fig1){ref-type="fig"}B and [S2](#mmc1){ref-type="supplementary-material"}B, arrow). Prior characterization of the *Cntd1* locus described the use of a start codon near the beginning of exon 3 (NCBI: DS033671), which would produce a 27.5-kDa endogenous protein and a 29.7-kDa tagged protein, matching the size we observe by WB ([Figures 1](#fig1){ref-type="fig"}A, 1B, and [S2](#mmc1){ref-type="supplementary-material"}A). We call this protein product CNTD1 short form. Since a non-specific band around the predicted size (40 kDa) for CNTD1^FH^ is observed, we undertook immunoprecipitation (IP) followed by WB using two independent anti-HA antibodies to determine whether a form of *Cntd1* ^*FH*^ exists that is obscured by this non-specific band. We observe the enrichment of the smaller 30-kDa band in the IP fraction ([Figure 1](#fig1){ref-type="fig"}C, arrow), loss of the non-specific band at ∼40 kDa, and no additional specific bands ([Figure 1](#fig1){ref-type="fig"}C).Figure 1CNTD1^FH^ Protein Is Smaller Than Predicted, Lacking an N-Terminal Cyclin Homology Required for CDK Interaction(A) Schematic of annotated full-length and short-form CNTD1, including predicted cyclin homology regions (red).(B) WB using antibodies against the HA epitope and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) from testis lysate of *Cntd1*^*+/+*^, *Cntd1*^*FH/+*^, and *Cntd1*^*FH/FH*^ mice. The green arrow indicates the CNTD1-specific band.(C) WB using the rabbit HA antibody against immunoprecipitated testis lysate from *Cntd1*^*FH/FH*^ mice using rat anti-HA antibody. The green arrow indicates the specific enriched band.(D) WB using the anti-HA antibody against testis lysate from *Cntd1*^*+/+*^ and *Cntd1*^*FH/FH*^ mice following normal and extended sonication. The green arrow indicates the specific band.(E) WB using the anti-HA antibody against yeast lysate expressing *Cntd1* short-form and full-length *Cntd1* from *P*~*ADH1*~.(F) N-terminal splice variants of mammalian CNTD1 homologs. Blue coloring denotes the conserved methionine of the short form in each homolog, with the immediate downstream amino acid sequences that follow colored black. In the mouse, Iso1 and Iso2 are equivalent to the annotated full-length CNTD1 and CNTD1 short form, respectively.(G) Yeast two-hybrid with full-length CNTD1 and CNTD1 short form (bait) with CDKs expressed (prey), grown on control (-LEU-TRP) and selective plates (-ADE-HIS-LEU-TRP).(H) WB using antibodies against CDK2 and CDK4 from anti-HA IP of *Cntd1*^*FH/FH*^ testis lysate. The stars indicate the non-specific bands.

We considered the possibility that standard sonication for protein extraction may not sufficiently liberate proteins associated with dense chromatin (T. Tran and J. Schimenti, personal communication). To determine whether this may explain the absence of a native 40-kDa CNTD1 isoform, we undertook an extended sonication technique, but we were unable to identify additional bands by WB ([Figure 1](#fig1){ref-type="fig"}D). We also considered whether the CNTD1 full-length protein could migrate smaller than predicted by WB. However, when we expressed constructs encoding the FLAG-HA-tagged full-length and short forms of CNTD1, we detected both forms of the protein by WB using an anti-HA antibody ([Figure 1](#fig1){ref-type="fig"}E). The CNTD1 short form migrates at the expected 30 kDa size. Thus, anti-HA antibodies can detect both full-length and short-form CNTD1, but they detect only the latter in mouse spermatocyte extracts, leading us to conclude that the major CNTD1 variant found in mouse testis is the short-form 30-kDa protein.

Comparative Analysis of CNTD1 Orthologs Reveals N-Terminal Variability {#sec2.2}
----------------------------------------------------------------------

Next, we examined the sequences of other CNTD1 orthologs. Sequence alignment shows strong conservation of CNTD1 across a diverse set of species, with a few important caveats. First, we identified an internal methionine that is absolutely conserved throughout the entire family ([Figure S3](#mmc1){ref-type="supplementary-material"}, blue). This methionine corresponds to the alternative start codon that produces the short form of CNTD1 in the mouse ([Figures 1](#fig1){ref-type="fig"}F and [S3](#mmc1){ref-type="supplementary-material"}). Second, we observe greater variability in the N-terminal portion of the protein upstream of this methionine ([Figure 1](#fig1){ref-type="fig"}F). This manifests as splice variants within species that exhibit multiple annotated isoforms ([Figure 1](#fig1){ref-type="fig"}F). Splicing always preferentially modifies the N terminus, leading to truncations that, at a minimum, constitute the short form of the protein. The koala ortholog exemplifies this pattern of variability ([Figure 1](#fig1){ref-type="fig"}F). It is important to note that one species, the American alligator, has only a single short isoform described that begins at the alternative methionine start site ([Figure S3](#mmc1){ref-type="supplementary-material"}, bottom row). These *in silico* findings underscore the evolutionary conservation of the CNTD1 short form and suggest its broader biological importance.

The CNTD1 N Terminus Mediates Interactions with Cyclin-Dependent Kinases {#sec2.3}
------------------------------------------------------------------------

CNTD1 has predicted homology to cyclin proteins across 3 regions: amino acids 57--88, 117--135, and 140--180 ([Figure 1](#fig1){ref-type="fig"}A). Truncation of the N terminus in the CNTD1 short form removes the first 85 amino acids, encompassing the majority of cyclin homology region 1 ([Figure 1](#fig1){ref-type="fig"}A). Using yeast two-hybrid analysis, we investigated whether the CNTD1 short form would associate with the CDKs that predominate in mouse spermatocytes, CDKs 1, 2, 4, 5, and 6 ([@bib1]; [@bib4]; [@bib6]; [@bib10]; [@bib63]). The full-length mouse CNTD1 interacts with CDK2 and CDK4 in yeast two-hybrid assays ([Figure 1](#fig1){ref-type="fig"}G, top half). The CNTD1 short form, however, fails to interact with any of the tested CDKs ([Figure 1](#fig1){ref-type="fig"}G, bottom half). To determine whether CDK2 and CDK4 interactions with CNTD1 exist *in vivo*, we immunoprecipitated CNTD1^FH^ from mouse testis using the anti-HA antibody and probed with antibodies against CDK2 and CDK4. IP with anti-HA antibodies failed to enrich for either CDK2 or CDK4 ([Figure 1](#fig1){ref-type="fig"}H), which is consistent with the conclusion that the CNTD1 short form is the predominant isoform in mouse and lacks the ability to interact with key prophase I CDKs.

CNTD1^FH^ Forms Discrete Foci in Pachytene Spermatocytes {#sec2.4}
--------------------------------------------------------

We next undertook immunohistochemistry on testis sections from *Cntd1* ^*+/+*^ and *Cntd1* ^*FH/FH*^ littermates. In testis sections from *Cntd1* ^*FH/FH*^ adults, we observed staining in primary spermatocytes using antibodies against the HA tag ([Figures 2](#fig2){ref-type="fig"} A, 2B, [S4](#mmc1){ref-type="supplementary-material"}A, and S4B). The localization of CNTD1 is restricted to prophase I cells, but appears to shuttle between the nucleus and cytoplasm in a stage-specific manner ([Figures 2](#fig2){ref-type="fig"}B and [S4](#mmc1){ref-type="supplementary-material"}B). Cytoplasmic localization is observed when staining intensity is increased by prolonged exposure to 3,3′-diaminobenzidine (DAB) exposure ([Figure S4](#mmc1){ref-type="supplementary-material"}B, square arrows), but staining remains consistently heaviest in the nucleus ([Figure S4](#mmc1){ref-type="supplementary-material"}B, arrows). No HA signal was observed in testis sections from wild-type littermates ([Figures 2](#fig2){ref-type="fig"}A and [S4](#mmc1){ref-type="supplementary-material"}A).Figure 2CNTD1^FH^ Localizes to Spermatocytes and Forms Discrete Foci at Pachytene(A and B) Immunohistochemistry using anti-HA antibody on formalin-fixed testis sections of *Cntd1*^*+/+*^(A) and *Cntd1*^*FH/FH*^ (B) mice, imaged at 200×. Bar, 300 μm.(C) Immunofluorescence staining using anti-HA (green) and anti-SYCP3 (red) antibodies on formalin-fixed testis sections of *Cntd1*^*+/+*^ and *Cntd1*^*FH/FH*^ mice, imaged at 200×. Right-hand panels are enlargements of the dotted-outline box. Lower right-hand box shows the anti-HA staining (white) with cytoplasmic staining and discreet foci.(D--H) Immunofluorescence staining on spread meiotic spermatocyte preparations from *Cntd1*^*FH/FH*^ mice using antibodies against the HA epitope (green) and SYCP3 (red). Leptonema (D), zygonema (E), pachynema (F), diplonema (G), and diakinesis (H) staged spermatocytes defined by SYCP3 morphology.(I) Quantification of HA foci (means ± SDs) in pachytene spermatocytes of *Cntd1*^*FH/FH*^ mice.(J) Enlarged image of dotted-outline box in (F). The closed arrowhead indicates strong intensity focus; the open arrowhead indicates low intensity focus.(K) Structural illumination microscopy rendering of (J).(L) Representative immunofluorescent staining of pachynema spermatocyte from *Cntd1*^*FH/FH*^ testis using antibodies against MLH1 (red), HA (green), and SYCP3 (white). The right panel is the enlarged insert of the dotted-outline box. Colocalization of HA and MLH1 is identified by the yellow arrow; the green arrow indicates HA-only foci.

We next used immunofluorescence staining on fixed testis sections and chromosome spread preparations. Using the same anti-HA antibody that we used in WB, which detected only the CNTD1^FH^ short orm, we observed discrete foci of CNTD1^FH^ at pachynema, distributed along the cores of the SC in testis sections and spread meiotic spermatocytes ([Figures 2](#fig2){ref-type="fig"}C--2L). For chromosome spreads, we used colocalization with the SC protein SYCP3 to assess the prophase I stage, providing a temporal profile of CNTD1^FH^ through prophase I. In leptonema, we observed diffuse nuclear staining of CNTD1^FH^, which accumulates along the SC in zygonema, with some foci observed along the SC ([Figures 2](#fig2){ref-type="fig"}D and 2E). Throughout pachynema, the diffuse nuclear staining of CNTD1^FH^ is no longer observed, being replaced by discrete foci along the SC at a frequency reminiscent of MutLγ numbers ([Figures 2](#fig2){ref-type="fig"}F and J--L; [@bib5]; [@bib40]). In early pachynema, localization of CNTD1^FH^ is observed in two distinct patterns: one population of cells has yet to accumulate any CNTD1^FH^ while a second population of cells shows increasing focus frequency ([Figure 2](#fig2){ref-type="fig"}I). By mid-pachynema, the focus frequency for CNTD1^FH^ is more homogeneous, at 27 ± 2.7, and persisting at 26.5 ± 3.3 in late pachynema ([Figure 2](#fig2){ref-type="fig"}I). By diplonema, the diffuse nuclear staining pattern resumes, but clear foci of HA signal remain associated with the SC ([Figures 2](#fig2){ref-type="fig"}G and 2H), and is lost by diakinesis.

From mid-pachynema onward, the number of HA-marked CNTD1 foci is consistently higher than focus frequencies for MLH1 and MLH3 ([@bib5]; [@bib40]; [Figures 2](#fig2){ref-type="fig"}I and [S1](#mmc1){ref-type="supplementary-material"}F). Dual staining of CNTD1^FH^ and MLH1 reveals the frequent presence of CNTD1^FH^ foci that do not co-localize with MLH1 foci but not vice versa ([Figure 2](#fig2){ref-type="fig"}L). However, while we observe colocalization of CNTD1^FH^ and MLH1, given the spatial distance over which fluorescent molecules excite, this only indicates proximity but does not imply direct interaction.

In addition to the temporospatial pattern of CNTD1^FH^ protein signal, we observed 2 distinct intensity patterns for CNTD1^FH^ foci during pachynema: the majority of HA-stained foci are bright and robust, while ∼1--5 foci per cell are of weaker intensity ([Figure 2](#fig2){ref-type="fig"}J). Increasing the imaging exposure time does not reveal additional faint foci that are not included in our quantitation nor do we observe any non-specific HA^+^ signal on chromosome spreads from wild-type males ([Figures S4](#mmc1){ref-type="supplementary-material"}C--S4F).

STA-PUT Protein Profiling {#sec2.5}
-------------------------

To define the temporal dynamics of CNTD1 appearance through prophase I relative to other key meiotic and cell-cycle regulators, an improved gravitational cell separation (STA-PUT) strategy was devised to allow the recovery of all stages of prophase I in a single procedure ([@bib8]; [@bib9]; [@bib58]). Meiotic chromosome spreads were prepared from 46 fractions and scored based upon SC morphology and presence of the phosphorylated histone variant γH2AFX ([@bib24]). The purity of STA-PUT-enriched fractions for each germ cell stage reached 67% leptonema, 45% zygonema, 89% pachynema, 79% diplonema, and 98% sperm across different fractions ([Figure 3](#fig3){ref-type="fig"} A). WB performed against proteins from the STA-PUT cell fractions resulted in a dynamic profile of protein levels using a battery of antibodies against meiosis regulators ([Figure 3](#fig3){ref-type="fig"}A), all compared to the dynamic expression of CNTD1 as detected by the HA tag. Detailed protein dynamics are delineated below, describing the data in [Figure 3](#fig3){ref-type="fig"}A.Figure 3STA-PUT Allows Isolation of Prophase I Stage-Specific Fractions Revealing Dynamic Protein Expression(A) STA-PUT assay performed on *Cntd1*^*FH/FH*^ testis single-cell suspensions. Top: quantification of STA-PUT cell fraction composition based on a minimum of 200 cells from spread preparations stained for SYCP3 and γH2AFX. WBs performed using the described antibodies against each STA-PUT fraction. Each WB row is a composite of four individual WBs performed and imaged under identical conditions.(B) Model depicting the 2 complexes identified as interacting partners with CNTD1 in our MS analysis: RFC (left) and SCF (right). The hypothesized interaction between RFC-PCNA and MutLγ is based upon *in vitro* experiments. The direct interactions with CNTD1 are depicted by black arrows.

### CNTD1^FH^ Expression (HA) {#sec2.5.1}

The peak HA signal (for CNTD1^FH^) is observed within fractions enriched for leptonema through pachynema, which is coincident with the staining observed in spread testis spermatocytes. As with our previous WBs ([Figure 1](#fig1){ref-type="fig"}), a single band of 30 kDa is observed in our isolated purified cell populations.

### Cell-Cycle Regulation {#sec2.5.2}

We observe the expression of CDK1 primarily in fractions enriched for leptotene through pachytene spermatocytes. A form of CDK1 with increased electrophoretic mobility is observed in pachynema. CDK2 has 2 characterized isoforms in the mouse; a 34-kDa short form (CDK2^34)^ lacking 48 amino acids compared with the longer 39-kDa (CDK2^39^) isoform generated by alternate splicing ([@bib22]). The abundance and modifications of the two isoforms differs across STA-PUT-enriched fractions.

The expression of CDK4 is observed in fractions enriched with leptotene, zygotene, pachytene, and sperm cells. CDK4 staining also shows an additional higher-molecular-weight-modified band that appears from leptonema until pachynema, in line with previously published localization patterns for CDK2 and CDK4 ([@bib4]).

### Meiotic Proteins {#sec2.5.3}

Expression of the early RING domain crossover factor RNF212 is observed coincident with the enrichment of leptotene cells and spans fractions enriched for leptonema though early pachynema. The appearance of the later-stage crossover protein HEI10 occurs from zygonema onward and persists in pachytene-enriched fractions. The expression of RNF212 and HEI10 fits the temporal progression of crossover sites gaining first, RNF212, followed by HEI10 observed in spread meiotic spermatocytes ([@bib51]). In addition, *Cntd1* mutants load RNF212 but fail to load HEI10 ([@bib27]). The appearance of the CNTD1^FH^ signal relative to RNF212 and HEI10 fits the temporal observations defined by chromosome spreads, with RNF212 observed earliest, followed by CNTD1^FH^, and then finally HEI10 ([@bib51]; [@bib53]).

MLH3 protein accumulation is observed from leptotene- through pachytene-enriched fractions. MLH3 antibody detects two different bands of similar molecular weight, indicating possible protein modification. Two isoforms of SYCP3 exist in the mouse, with the longer form a consequence of N-terminal extension ([@bib3]). Both isoforms of SYCP3 are present in leptotene- through diplotene-enriched fractions. The large form is predominant in the sperm- and leptotene-enriched fractions and the short form is predominant in the diplotene-enriched fractions. Both forms of SYCP3 appear to have multiple bands migrating around the similar molecular weight, indicating protein modification. The central element SYCP1 forms between synapsed chromosomes during zygotene and pachytene, and appears in STA-PUT fractions enriched in zygotene through pachytene spermatocytes.

### DNA Repair Factors {#sec2.5.4}

Following DSB formation, phosphorylation of H2AFX on serine 139 (referred to as γH2AFX) occurs, leading to the recruitment of repair factors and chromatin remodeling. On meiotic spread chromosomes, γH2AFX is observed throughout leptotene as DSBs occur and persists during DSB repair. During zygotene and pachytene γH2AFX appears around the XY chromosomes, forming the sex body. Detection of γH2AFX in the STA-PUT fractions is consistent with these cytological observations. γH2AFX appears as multiple bands throughout leptonema and becomes a more discrete band in pachytene-enriched fractions. These observations suggest that early, DSB-associated γH2AFX may undergo different modifications than that of the XY-associated protein.

Following DSB formation and early processing, RecA homologs RAD51 and DMC1 undertake strand invasion to repair from homologous DNA templates. Consistent with RAD51 staining on chromosome spreads, we observe RAD51 in leptotene through pachytene-enriched fractions, with levels decreasing as the fractions start to contain diplotene cells.

Mass Spectrometry (MS) of CNTD1^FH^-Enriched STA-PUT Fractions Reveals Interactions with RFC and SCF Complexes {#sec2.6}
--------------------------------------------------------------------------------------------------------------

Stage-matched prophase I cell fractions from *Cntd1* ^*+/+*^ and *Cntd1* ^*FH/FH*^ testes were used for IP against the HA epitope, followed by MS to identify interacting proteins (green box in [Figure S5](#mmc1){ref-type="supplementary-material"}). A total of 588 proteins ([Table S1](#mmc2){ref-type="supplementary-material"}) were enriched in the CNTD1^FH^ sample compared with *Cntd1* ^*+/+*^. A total of 181 proteins were identified by ≥2 peptides. Given the localization pattern and function in crossover formation, we did not identify any proteins important for class I crossovers (MSH4, MSH5, MLH1, MLH3, RNF212, HEI10, or CDK2), nor did we identify any CDKs, consistent with the predominant expression of *Cntd1* short form in mouse testis. Instead, most CNTD1-interacting proteins fall into Gene Ontology groups involved in cellular and metabolic processes ([Figure S6](#mmc1){ref-type="supplementary-material"}A). Of these, we prioritized our continued analysis based on protein interactors that may explain crossover designation, cell-cycle progression, and the recent understanding of the role of post-translational modifications in driving these functions during meiosis ([@bib2]; [@bib15]; [@bib53]). Based on these criteria, two specific complexes were of particular interest ([Figure 3](#fig3){ref-type="fig"}B). First, CNTD1^FH^ interacts with components of the RFC complex, which in somatic cells acts in the recruitment/activation of the DNA mismatch repair pathway ([@bib11]; [@bib18]; [@bib31]). Second, CNTD1^FH^ interacts with many proteins belonging to the ubiquitylation pathway ([Figures 3](#fig3){ref-type="fig"}B and [S6](#mmc1){ref-type="supplementary-material"}B), including components of the SKP1-Cullin-Fbox (SCF; reviewed in [@bib39]), namely the E2 conjugating enzyme CDC34 ([Figures 3](#fig3){ref-type="fig"}B and [S6](#mmc1){ref-type="supplementary-material"}B).

### RFC Complex {#sec2.6.1}

RFC is a pentameric complex, consisting of RFC1--5, which loads proliferating cell nuclear antigen (PCNA) onto DNA during DNA replication ([Figure 3](#fig3){ref-type="fig"}B; [@bib41]). RFC and PCNA have been implicated in the activation of MutL endonucleases ([@bib11]; [@bib18]; [@bib31]; [@bib65]). Our MS data revealed CNTD1 interaction with RFC3 and RFC4 ([Table S1](#mmc2){ref-type="supplementary-material"}), which was confirmed by anti-HA-IP followed by WB using anti-RFC3 and RFC4 antibodies ([Figure 4](#fig4){ref-type="fig"} A). WB analysis on whole-testis lysate from *Cntd1* ^*+/+*^ and *Cntd1* ^*−/−*^ mice demonstrated no difference in the total protein levels of RFC3, RFC4, or PCNA ([Figure 4](#fig4){ref-type="fig"}B). In STA-PUT fractions from *Cntd1* ^*+/+*^ testes, we detected RFC3 and RFC4 protein in fractions enriched for leptonema through pachynema cells, while PCNA persists until diplonema ([Figure 4](#fig4){ref-type="fig"}C). In STA-PUT fractions from *Cntd1* ^*−/−*^ testes, RFC3 and RFC4 protein levels were decreased in lanes representing mostly pachytene cells, compared to similar lanes in WBs from STA-PUT-sorted *Cntd1* ^*+/+*^ fractions ([Figure 5](#fig5){ref-type="fig"} A).Figure 4CNTD1 Mutation Leads to a Decrease in CDC34 Levels Compared to Wild Type(A and B) WB using antibodies against CNTD1^FH^-interacting proteins from immunoprecipitated material using anti-HA antibody from *Cntd1*^*FH/FH*^ mice (A) and from testis lysate (B) of *Cntd1*^*FH/FH*^, *Cntd1*^*FH/−*^, and *Cntd1*^*−/−*^ mice.(C) STA-PUT assay performed on *Cntd1*^*FH/FH*^ testis single-cell suspensions showing expression of CNTD1^FH^ interacting factors and downstream interactors relative to prophase I stage. Top panel: quantification of STA-PUT cell fraction composition based on a minimum of 200 cells from spread preparations stained with SYCP3 and γγH2AFX antibodies. WBs were performed using the described antibodies against each STA-PUT fraction.(D) WB using antibodies against CDC34 and GAPDH on lysate from whole testis, *Wild-type*, *Cntd1*^*−/−*^, and *Mlh1*^*−/−*^ mice.(E) WB against predicted downstream CDC34 targets and GAPDH control.(F) WEE1 inhibitory phosphorylation on CDK1 and CDK2.Figure 5CNTD1 Mutation Causes a Decrease in Nuclear RFC4 Signal and Persistent Increased Nuclear Signal of PCNA in Prophase I Cells(A) STA-PUT assay performed on *Cntd1*^*−/−*^ testis single-cell suspension from 12 adult mice showing expression of RFC3, RFC4, PCNA, and CDC34 relative to prophase I stage. Top panel: quantification of STA-PUT cell fraction composition based on a minimum of 200 cells from spread preparations stained with SYCP3 and γH2AFX antibodies. WBs were performed using the described antibodies against each STA-PUT fraction. Each WB row is an amalgamation of 4 individual WBs performed and imaged under identical conditions.(B--G) Immunofluorescence staining of pachynema staged spread meiotic spermatocytes from *Cntd1*^*FH/FH*^ (B, D, and F) and *Cntd1*^*−/−*^ (C, E, and G) mice using RFC3 (B and C), RFC4 (D and E), and PCNA (F and G) antibodies.(H and I) Immunofluorescence staining using antibodies against RFC4 (green) and SYCP3 (red) on formalin-fixed testis sections of *Cntd1*^*FH/FH*^ (H) and *Cntd1*^*−/−*^ (I) mice, imaged at 200×. The white bars indicate the prophase I cells. The arrowheads indicate spermatogonia and the arrows indicate spermatocytes. The right-hand panels show representative images of the prophase I stages from enlarged sections of (H) and (I), respectively, staged by SYCP3 morphology.(J and K) Immunofluorescence staining using antibodies against PCNA (green) and SYCP3 (red) on formalin-fixed testis sections of *Cntd1*^*FH/FH*^ (J) and *Cntd1*^*−/−*^ (K) mice, imaged at 200×. The white bars indicate the prophase I cells. The arrowheads indicate spermatogonia and the arrows indicate spermatocytes. The right-hand panels show representative images of the prophase I stages from enlarged sections of (J) and (K), respectively, staged by SYCP3 morphology.

Immunofluorescence staining on spread meiotic chromosomes using antibodies against RFC3 and RFC4 revealed faint nuclear staining and focus formation along regions of the synaptonemal complex in pachynema. In pachytene spermatocytes from *Cntd1* ^*−/−*^ males, the overall nuclear staining of RFC3 and RFC4 was reduced, as was the specific number of RFC3/4 foci along autosomal synaptonemal complexes compared with that observed in *Cntd1* ^*FH/FH*^ cells ([Figures 5](#fig5){ref-type="fig"}B--5E). By contrast, PCNA immunofluorescence staining in pachytene spermatocytes from *Cntd1* ^*FH/FH*^ males revealed diffuse nuclear staining in addition to discrete foci of PCNA along chromosome cores, some reminiscent of the patterning observed when staining for class I crossover proteins ([Figure 5](#fig5){ref-type="fig"}F). By contrast, PCNA staining in pachytene spermatocytes from *Cntd1* ^*−/−*^ males was more intense across the entire nucleus, including the signal observed along the synaptonemal complex ([Figure 5](#fig5){ref-type="fig"}G).

Immunolocalization of RFC4 protein in testis sections revealed a robust RFC4 signal within the nuclei of spermatogonia and primary spermatocytes in wild-type testes ([Figure 5](#fig5){ref-type="fig"}H), with a steadily increasing signal for RFC4 as prophase I progresses ([Figure 5](#fig5){ref-type="fig"}B). In testis sections from *Cntd1* ^*−/−*^ males, we observe persistent, stronger staining of RFC4 in spermatogonia compared with *Cntd1* ^*FH/FH*^ males ([Figure 5](#fig5){ref-type="fig"}I), but decreased staining in the primary spermatocytes at all stages of prophase I relative to that observed in *Cntd1* ^*+/+*^ spermatocytes ([Figures 5](#fig5){ref-type="fig"}H and 5I, right-hand gray panels, and [S7](#mmc1){ref-type="supplementary-material"}).

PCNA staining of *Cntd1* ^*+/+*^ testis revealed nuclear staining in occasional spermatogonia and all of the primary spermatocytes ([Figure 5](#fig5){ref-type="fig"}J). Similar staining is observed in primary spermatocytes in *Cntd1* ^*−/−*^ males, with an increased intensity of PCNA signal due to the higher proportion of spermatocytes compared to that observed in adult *Cntd1* ^*+/+*^ testis ([Figures 5](#fig5){ref-type="fig"}K and [S7](#mmc1){ref-type="supplementary-material"}). However, the staining intensity in individual sub-stages of prophase I appears persistently more robust in spermatocytes from *Cntd1* ^*−/−*^ males than in wild type ([Figures 5](#fig5){ref-type="fig"}J and 5K, right-hand gray panels, [S7](#mmc1){ref-type="supplementary-material"}). These results demonstrate the robust localization of RFC and PCNA in late-stage primary spermatocytes, distinct from their expected staining in cells undergoing DNA replication (e.g., proliferating spermatogonia). In this regard, our data suggest that RFC and PCNA may play a role in DSB repair during meiosis that is analogous to their role in DNA repair in somatic cells in regard to MutL complexes ([@bib41]).

### CDC34 E2 Conjugating Enzyme {#sec2.6.2}

The SCF complex is the most widely characterized of the superfamily of Cullin/RING ubiquitin ligases (CRLs) ([@bib61]). The SCF core complex works together with E1 (activating) and E2 (conjugating) enzymes to define ubiquitylation substrates ([Figure 3](#fig3){ref-type="fig"}B; [@bib52]). Our MS data revealed that CNTD1 interacts with 22 components of the ubiquitylation/de-ubiquitylation family ([Figure S6](#mmc1){ref-type="supplementary-material"}B; [Table S1](#mmc2){ref-type="supplementary-material"}), including the E2 conjugating enzyme CDC34.

The distribution of CDC34 protein across STA-PUT fractions from *Cntd1* ^*+/+*^ males primarily revealed protein in fractions enriched with round spermatids, sperm, leptotene, and zygotene cell types ([Figure 4](#fig4){ref-type="fig"}C, fractions 32--42). IP-WB confirmed the interactions between CNTD1^FH^ and CDC34 ([Figure 4](#fig4){ref-type="fig"}A), while WB from whole-testis lysates revealed that CDC34 levels in *Cntd1* ^*−/−*^ mutants were drastically decreased compared with those of *Cntd1* ^*FH/FH*^ animals ([Figure 4](#fig4){ref-type="fig"}B). Because of this interaction, we asked whether CDC34 levels were similarly altered in crossover mutants for genes acting downstream of CNTD1. CDC34 protein levels were reduced in *Mlh1* ^*−/−*^ mice to a similar extent as those observed in *Cntd1* ^*−/−*^ mice ([Figure 4](#fig4){ref-type="fig"}D). The WB profile of CDC34 protein across STA-PUT fractions from *Cntd1* ^*−/−*^ males, where prophase I cells are present but sperm is absent, showed a similar drastic reduction in CDC34 protein ([Figure 5](#fig5){ref-type="fig"}K). Therefore, the lack of CDC34 protein is a consequence of a failure to form a competent crossover complex and subsequent lack of later-stage cells.

Immunofluorescence staining on testis sections revealed the most prominent CDC34 signal in round and elongating spermatids of *Cntd1* ^*FH/FH*^ males. *Cntd1* ^*−/−*^ males, lacking these post-meiotic cell types, failed to show significant CDC34 staining ([Figures 6](#fig6){ref-type="fig"}A and 6B).Figure 6CDC34 Levels Are Decreased and Downstream Targets Are Mislocalized in CNTD1 Mutants(A and B) Immunofluorescence using antibodies against CDC34 (green) and SYCP3 (red) on formalin-fixed testis sections of *Cntd1*^*FH/FH*^ (A) and *Cntd1*^*−/−*^ (B) mice, imaged at 200×. The white bars indicate the prophase I cells. The right-hand gray panels show representative images of the prophase I stages from enlarged sections of (A) and (B), respectively, staged by the morphology of the synaptonemal complex from SYCP3 staining.(C--J) Immunofluorescence using antibodies against WEE1 (C and D) and its targets, including pan-tyrosine15 (E and F), CDK1 (G and H), and CDK2 (I and J), on formalin-fixed testis sections of *Cntd1*^*FH/FH*^ (left column panels C, E, G, and I) and *Cntd1*^*−/−*^ (right column panels D, F, H, and J), imaged at 200×. The white bars indicate the prophase I cells; the arrow highlights the spermatocytes. The right-hand gray panels show representative images of the prophase I stages from enlarged sections, staged by SYCP3 morphology.

Targets of CDC34 Are Drivers of Cell-Cycle Progression and Crossover Regulation during Prophase I {#sec2.7}
-------------------------------------------------------------------------------------------------

CDC34 targets the WEE1 kinase for degradation in mitosis ([@bib44]). WEE1 functions as a mitotic inhibitor ([@bib44]; [@bib47]; [@bib59]; [@bib60]; [@bib64]), specifically inhibiting the CDK1 component of maturation-promoting factor (MPF) to prevent premature metaphase I entry ([@bib19]; [@bib47]; [@bib49]; [Figure 4](#fig4){ref-type="fig"}F). WEE1 degradation thus allows MPF activation to facilitate cell-cycle progression. Accordingly, WEE1 staining in fixed testis sections revealed strong cytoplasmic and diffuse faint nuclear localization in prophase I spermatocytes from *Cntd1* ^*FH/FH*^ males, with the nuclear localization disappearing by diplonema ([Figure 6](#fig6){ref-type="fig"}C).

Given the lack of post-spermatocyte cells in *Cntd1* ^*−/−*^ males and the decrease in CDC34 protein in these animals, we hypothesized that the regulation of WEE1 was defective in *Cntd1* ^*−/−*^ males. WEE1 was decreased in protein extracts from testes of *Cntd1* ^*−/−*^ males compared with *Cntd1* ^*FH/FH*^ males, whereas CDK1 and CDK2 protein levels were not significantly altered ([Figure 4](#fig4){ref-type="fig"}E). The nuclear localization of WEE1, however, is observed throughout prophase I and remains elevated at diplonema in spermatocytes of *Cntd1* ^*−/−*^ males rather than diminishing as in wild-type testes ([Figure 6](#fig6){ref-type="fig"}D).

WEE1 inhibits CDK1 and CDK2 activity by phosphorylation on tyrosine 15 ([@bib23]; [@bib25]; [@bib37]; [@bib48]), but phospho-specific antibodies against tyrosine 15 of CDK1 and CDK2 did not reveal any significant change in whole-testis lysate from *Cntd1* ^*−/−*^ males compared to *Cntd1* ^*FH/FH*^ animals ([Figure 4](#fig4){ref-type="fig"}E). Therefore, to assess prophase I stage-specific changes in WEE1 phosphorylation, we stained testis sections from *Cntd1* ^*FH/FH*^ and *Cntd1* ^*−/−*^ males using a pan-CDK phospho-tyrosine 15 antibody ([Figures 6](#fig6){ref-type="fig"}E and 6F). We observed strong cytoplasmic staining of early prophase I *Cntd1* ^*FH/FH*^ spermatocytes that is lost by diplonema ([Figure 6](#fig6){ref-type="fig"}E). By contrast, we observed the retention of the cytoplasmic pan-CDK phospho-tyrosine 15 signal throughout prophase I in testis sections of *Cntd1* ^*−/−*^ males ([Figure 6](#fig6){ref-type="fig"}F).

CDK1 and CDK2 staining in *Cntd1* ^*FH/FH*^ cells appear to be dynamic between the cytoplasm and nucleus throughout prophase I ([Figures 6](#fig6){ref-type="fig"}G and 6I). In early prophase I, CDK1 and CDK2 are distributed between both cellular compartments, but by diplonema show strong nuclear staining. By contrast, staining of CDK1 and CDK2 in testis sections from *Cntd1* ^*−/−*^ males reveals much less-intense nuclear signal with only faint cytoplasmic staining and no localization in the nucleus by diplonema ([Figures 6](#fig6){ref-type="fig"}H and 6J). These data suggest that SCF is misregulated in *Cntd1* ^*−/−*^ males relative to *Cntd1* ^*FH/FH*^, leading to decreased CDC34 levels. This in turn results in increased WEE1^+^ cells within the seminiferous epithelium of *Cntd1* ^*−/−*^ males coupled with a decrease in CDK1 and CDK2 staining in the nucleus of late prophase I cells and a persistence of inhibited CDKs in the cytoplasm ([Figures 6](#fig6){ref-type="fig"}G--6L). We postulate that the insufficient degradation of WEE1 arising from the loss of CNTD1 and CDC34 directly contributes to the failure of cell-cycle progression.

*In Vitro* Inhibition of WEE1 Facilitates Progression into Metaphase I and Is a Prerequisite for Spindle Assembly Checkpoint (SAC) Activation {#sec2.8}
---------------------------------------------------------------------------------------------------------------------------------------------

Following prophase I, cells progress to metaphase I, the stage at which the SAC monitors correct microtubule attachment before entry into anaphase I. We postulated that spermatocytes from *Cntd1* ^*−/−*^ males fail to progress past prophase I to the metaphase-to-anaphase transition, and thus do not activate the SAC. To test this, we cultured prophase I cells from *Cntd1* ^*+/+*^ and *Cntd1* ^*−/−*^ males for short periods of time in the presence of adavosertib (MK-1775) (0.25--10 μg/mL), a WEE1 kinase inhibitor, and/or nocodazole (1--80 μg/mL), a microtubule polymerization inhibitor. As a readout for drug activity and metaphase entry/progression, we used WB analysis to monitor the levels of the anaphase I inhibitor MAD2L2 and inhibitory phospho-tyrosine 15 on CDK1 and CDK2 for SAC and WEE1 activity, respectively.

Cells from *Cntd1* ^*−/−*^ males showed reduced CDK1 and CDK2 inhibitory phosphorylation when treated with adavosertib alone, while cells treated with nocodazole alone failed to show any increase in the levels of MAD2L2 ([Figures 7](#fig7){ref-type="fig"}A and 7B). Only when both drugs were applied to these cells was the inhibition of anaphase I progression observed, reflected by an increase in MAD2L2 protein levels ([Figures 7](#fig7){ref-type="fig"}A and 7B). Accordingly, whole-testis lysates from *Cntd1* ^*−/−*^ males showed a decrease in MAD2L2 protein levels compared to those of wild-type males ([Figure 7](#fig7){ref-type="fig"}C), which is indicative of a reduced number of cells completing prophase I.Figure 7*In Vitro* Short-Term Cultures Reveal a WEE1-Dependent Meiotic Crossover Checkpoint for Progression into Metaphase I(A) WB using antibodies against WEE1 inhibitory phosphorylation targets CDK1-pY15 and CDK2-pY15 and anaphase inhibitor MAD2L2 following the treatment of cultured spermatocytes from *Cntd1*^*+/+*^*and Cntd1*^*−/−*^ males with adavosertib, nocodazole, or both drugs. The triangles indicate increasing drug concentrations (see [Method Details](#sec4.4){ref-type="sec"}).(B) Analysis of protein signal from WB in (A) divided by GAPDH signal, relative to the V.O. (vehicle only) control.(C) WB against MAD2L2 in whole testis lysates from *Cntd1*^*+/+*^*and Cntd1*^*−/−*^ males.(D) Inhibitory phosphorylation of CDK1 and CDK2 by WEE1, which itself is degraded *in vivo* by CDC34 or inhibited by adavosertib treatment. WEE1 degradation/inhibition allows the activation of the MPF and progression into metaphase I. The spindle assembly checkpoint (SAC) monitors the correct attachment of microtubules and prevents the progression from metaphase I to anaphase I. Nocodazole inhibits microtubule formation and promotes/maintains the SAC.(E) Model of CNTD1 function based on results presented in the present article.

To our surprise, cultured spermatocytes from wild-type males showed a similar requirement for both adavosertib and nocodazole treatment to elicit a MAD2L2 response ([Figures 7](#fig7){ref-type="fig"}A and 7B). These data indicate that the inhibition of WEE1 is required for progression into metaphase and that the treatment of wild-type spermatocytes with adavosertib results in the massive and rapid induction of metaphase I entry, thus permitting progression through to anaphase I. Without adavosertib, too few cells naturally progress into metaphase to be detected by MAD2L2 protein induction ([Figure 7](#fig7){ref-type="fig"}D).

Discussion {#sec3}
==========

Crossovers are essential for the accurate segregation of homologous chromosomes during meiosis I. The present article shows that CNTD1^FH^ foci are found in a similar distribution and frequency to those of MutLγ, often co-localizing with this complex. Approximately 1--5 MLH1-independent foci exist per cell, reminiscent of the number of crossovers expected to form through MutLγ-independent mechanisms ([@bib26]). Thus, we propose that CNTD1 localizes to all nascent crossover sites, not only those destined to form MutLγ-dependent crossovers. We do not find any discrete CNTD1^FH^ signal before pachynema, suggesting that CNTD1 accumulates at a time when class I and II crossovers are becoming designated.

Using an epitope-tagged allele of *Cntd1,* we demonstrate that a short form of CNTD1, arising from the translation of an internal start codon in exon 3, predominates in the mouse testis. Two lines of evidence support this conclusion: (1) migration of CNTD1-FH on WB and the corroborating localization of the tagged protein on meiotic chromosome cores in prophase I (Figures [1](#fig1){ref-type="fig"}B--1E and [2](#fig2){ref-type="fig"}C--2L) and (2) multiple anti-HA antibodies can detect both full-length and short forms of the protein when expressed in yeast, and they migrate relative to their predicted size, indicating that if a full-length protein did exist in spermatocytes, we would be able to detect it. The CNTD1 short-form protein lacks the first cyclin homology domain and is incapable of associating directly with any known CDKs. Our MS and IP-WB data, however, show that the CNTD1 short form can interact with the regulators of CDK activity, thereby providing an indirect mechanism by which progression through the cell cycle can be modulated following appropriate crossing over. We cannot exclude the possibility that the CNTD1 short form maintains some cyclin-like functions since it still contains two cyclin homology domains with predicted structural similarity to cyclin A. In fact, these cyclin domains may be critical for protein translocation between the cytoplasm and the nucleus at defined stages during prophase I, as observed in CNTD1 short-form staining ([Figure S4](#mmc1){ref-type="supplementary-material"}) and as has previously been shown for cyclin domain-containing proteins ([@bib36]). We also cannot rule out that the full-length version of CNTD1 exists in low, undetectable levels or that it is more predominant in females. In testis from male mice, however, we find only a single band migrating at a size that corresponds with the epitope-tagged short form of CNTD1, while the same antibodies used on chromosome spread preparations localize exclusively to sites that correspond with nascent crossovers and mostly correspond to MutLγ localization.

Although the internal methionine start site used to generate the short-form mouse CNTD1 is absolutely conserved, the CNTD1 N terminus shows variability across and within species, with many organisms showing multiple isoforms in this region. These differences may reflect divergent CNTD1 functions, with some homologs retaining the ability to maintain direct CDK interactions and act as canonical cyclins, while others must exert their effects indirectly.

Our MS identified interactions between CNTD1 and components of the RFC complex. While RFC and PCNA are required for the activity of human and yeast MutLα *in vitro* ([@bib18]; [@bib31]; [@bib65]), yeast MutLγ displays activity independent of these proteins ([@bib42]). However, more recent studies (currently in preprint form) have demonstrated that RFC and PCNA activate mammalian MutLγ ([@bib14]; [@bib38]). While no information exists to describe the interaction between RFC and PCNA complexes in mammalian germ cells *in vivo*, it is likely, given the observations from mitotic, biochemical, and *in vitro* assays, that these complexes interact, potentially in a DNA substrate-specific manner. Moreover, our previous studies have demonstrated the importance of PCNA in meiotic prophase I in the mouse ([@bib54]). In the present work, we observe a decreased cellular signal of RFC4 but a stronger nuclear staining pattern of PCNA throughout prophase I in testis sections from *Cntd1* mutants. On meiotic spread preparations, PCNA localization along the SC increases in the absence CNTD1, coincident with the decreased localization of RFC3/4. Previous characterizations of *Cntd1* ^*GT/GT*^ male mice revealed normal prophase I progression before crossover formation and normal DSB formation and repair kinetics with no persistent DSBs observed ([@bib27]). The progression of spermatocytes through to pachynema of prophase I in testis from *Cntd1* ^*−/−*^ animals ([Figures 5](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"}) indicates that the kinetics of early DSB induction and repair are largely normal. The persistent strong nuclear and SC staining of PCNA that we observe within *Cntd1* null mutants is therefore not a consequence of the failure to undergo appropriate early DNA repair events. This is further supported by diakinesis spreads that show decreased bivalent formation in *Cntd1* ^*−/−*^ animals, but not fragmented chromosomes forming as a result of unrepaired DSBs. Based on these observations, we propose that the persistent PCNA signal (and not RFC) is not related to ongoing DNA synthesis associated with meiotic recombination in *Cntd1* ^*−/−*^ animals, but is instead a prelude to active crossover formation, with CNTD1-RFC-PCNA being required to localize proteins at the correct location and time to achieve class I crossovers. New observations from the Cejka and Hunter labs support our observations and our conclusion that PCNA-RFC interactions facilitate MutLγ-stimulated crossover formation ([@bib14]; [@bib38]).

CNTD1 interacts with several components of the SCF ubiquitylation complex ([Figure S6](#mmc1){ref-type="supplementary-material"}B), including the E2 conjugating enzyme CDC34. Although we have not identified the partner E3 ubiquitin ligase(s) that functions with CDC34, previous findings in *Xenopus* identified the cell-cycle kinase WEE1 as a specific target of CDC34 ([@bib44]). WEE1 exerts inhibitory effects through the phosphorylation of CDK1 and CDK2, and its removal enables mitotic cell-cycle progression ([@bib25]; [@bib47]; [@bib67]). We find a similar mechanism functioning during meiotic prophase I in the male mouse. In this context, WEE1 phosphorylation of CDK1 maintains MPF in an inactive state and prevents cyclin B-CDK1-induced progression to metaphase. *Cntd1* null mutants show a decreased CDC34 signal, a retention of WEE1 in the nucleus throughout prophase I, continued inhibitory phosphorylation of its targets within the cytoplasm, and a consequent failure to localize CDK1 and CDK2 within the nucleus of late-stage prophase I cells. However, the total WEE1 signal from the testis of *Cntd1* ^*−/−*^ animals showed a decrease compared with that of *Cntd1* ^*FH/FH*^ animals. While we cannot fully explain this difference, the lack of post-meiosis I cells in the *Cntd1* ^*−/−*^ animals or the difference in total protein found in the cytoplasmic versus nuclear compartments may account for the difference in total protein. These observations strongly argue that CNTD1 acts upstream of WEE1 through association with CDC34 and relieves the inhibitory effects of WEE1 phosphorylation, thereby coordinating the timing of cell-cycle progression with proper crossover formation.

To clarify the connection between CNTD1 and cell-cycle progression, we devised a strategy to investigate how CNTD1-mediated WEE1 inhibition could perturb the completion of prophase I. To test this in an *in vitro* short-term culture system, we used the small-molecule WEE1 inhibitor adavosertib in conjunction with the metaphase-to-anaphase inhibitor nocodazole. Only with combined treatment using both drugs were we able to observe the inhibition of metaphase I progression, indicative of an induced SAC, and such a result was observed in spermatocytes from both wild-type and *Cntd1* mutant males. These results demonstrate a requirement for WEE1 degradation/inhibition to allow metaphase I entry and thus to facilitate progression to the metaphase-anaphase boundary ([Figure 7](#fig7){ref-type="fig"}D).

Collectively, our work defines two modes of action for CNTD1 in meiosis: simultaneously stimulating crossover formation through association with RFC while concomitantly regulating cell-cycle progression through interactions with CDC34 and subsequent ubiquitylation of WEE1 ([Figure 7](#fig7){ref-type="fig"}E). While these activities are distinct, the localization of both CNTD1^FH^ and CDK2 at crossover sites, together with the fact that CDK1 and CDK2 are both downstream targets of the SCF complex, support the integrated regulation by CNTD1 of the processes governing crossover formation and cell-cycle progression. Despite the persistent colocalization of CNTD1 and CDK2 in recombination foci throughout the ∼7 days of mouse pachynema, we cannot find any evidence of a physical interaction between these two proteins *in vivo*. Instead, our findings show that CNTD1 interacts with key players of crossover formation and cell-cycle progression and that the loss of CNTD1 leads to the misregulated localization of these factors. We propose that CNTD1 functions to coordinate these processes, indirectly affecting the activity of cell-cycle regulators and implicating CNTD1 as a stop-go regulator mechanism, monitoring crossover formation akin to a crossover-specific checkpoint, which may also be activated by the cellular machinery downstream of CNTD1. CNTD1 interactions with RFC in the context of the RAD17-RFC complex, an established cell-cycle checkpoint mediator ([@bib50]), could provide additional crosstalk and control of these pathways ([Figure 7](#fig7){ref-type="fig"}E). While our findings have immediate implications for the timing and control of prophase I in the male mouse, the dual nature of CNTD1 pathway interactions that we have uncovered here and the potential of variable splicing at the N terminus implicate CNTD1 as a regulatory nexus throughout the animal kingdom.

Limitations of Study {#sec3.1}
--------------------

The present article describing our elucidation of CNTD1 function was submitted for consideration in November 2019. Reviewers' comments were received in February 2020, but we were unable to fully address some of the points due to the outbreak of coronavirus disease 2019 (COVID-19). While we addressed the vast majority of points raised by the reviewers, due to our inability to undertake additional experiments, we have identified three limitations to our study. First, while we have identified a short-form CNTD1 protein by WB, a reviewer suggested a modified protein extraction technique to identify whether an additional CNTD1 form could be observed. Second, while we have shown interactions of CNTD1 with components of the RFC complex and CDC34 by unbiased (MS) and biased (IP-WB) methods, because of the importance of these interactions, a reviewer asked for further confirmation of interaction by other biochemical methods. Finally, reviewers asked us to build on data in [Figure 4](#fig4){ref-type="fig"} and data within [Figure 7](#fig7){ref-type="fig"} with the inclusion of drug treatment on an additional meiotic crossover mutant (*Mlh1* ^*−/−*^). Such studies will be pursued once our laboratories reopen.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**CDC34ProteintechCat\# 10964-2-AP; RRID: [AB_2077925](nif-antibody:AB_2077925){#interref50}CDK1MilliporeCat\# MAB8878; RRID: [AB_2074771](nif-antibody:AB_2074771){#interref55}CDK1-pY15AbcamCat\# ab47594; RRID: [AB_869073](nif-antibody:AB_869073){#interref60}CDK2Santa CruzCat\# sc-163; RRID: [AB_631215](nif-antibody:AB_631215){#interref65}CDK2-pY15AbcamCat\# ab76146; RRID: [AB_1310069](nif-antibody:AB_1310069){#interref70}CDK4Cell SignalingCat\# 12790S; RRID: [AB_2631166](nif-antibody:AB_2631166){#interref75}Cyclin B1Cell SignalingCat\# 4138S; RRID: [AB_2072132](nif-antibody:AB_2072132){#interref80}GAPDHInvitrogenCat\# MA5-15738-HRP; RRID: [AB_2537659](nif-antibody:AB_2537659){#interref85}HA (Rabbit)Cell SignalingCat\# 3724S; RRID: [AB_1549585](nif-antibody:AB_1549585){#interref90}HA (Rat)RocheCat\# 11867423001; RRID: [AB_390918](nif-antibody:AB_390918){#interref95}HEI10AbcamCat\# ab71977; RRID: [AB_1310045](nif-antibody:AB_1310045){#interref100}MLH1BD BiosciencesCat\# 550838; RRID: [AB_2297859](nif-antibody:AB_2297859){#interref105}MLH3Custom made ([@bib26])N/AMAD2L2ProteintechCat\# 12683-1-AP; RRID: [AB_2139530](nif-antibody:AB_2139530){#interref110}Pan CDK p-Y15AbcamCat\# ab133463; RRID: [AB_2811262](nif-antibody:AB_2811262){#interref115}PCNAProteintechCat\# 10205-2-AP; RRID: [AB_2160330](nif-antibody:AB_2160330){#interref120}RAD51MilliporeCat\# PC130-100UL; RRID: [AB_569857](nif-antibody:AB_569857){#interref125}RFC3ProteintechCat\# 11814-1-AP; RRID: [AB_2178470](nif-antibody:AB_2178470){#interref130}RFC4ProteintechCat\# 10806-1-AP; RRID: [AB_2178477](nif-antibody:AB_2178477){#interref135}RNF212NovusCat\# NBP1-83471; RRID: [AB_11030667](nif-antibody:AB_11030667){#interref140}SYCP1AbcamaCat\# b15090; RRID: [AB_301636](nif-antibody:AB_301636){#interref145}SYCP3Custom made ([@bib35])N/AWEE1NovusCat\# NBP1-33506; RRID: [AB_2215876](nif-antibody:AB_2215876){#interref150}γH2AFXMilliporeCat\# 05-636; RRID: [AB_309864](nif-antibody:AB_309864){#interref155}**Chemicals, Peptides, and Recombinant Proteins**AdavosertibMedChemExpressCat\# HY-10993NocodazoleSigma AldrichCat\# SML1665-1ML**Experimental Models: Organisms/Strains***M. musculus* C57BL/6JThe Jackson Laboratory000664*S. cerevisiae* Y2H GoldTakarabio630498**Oligonucleotides**CNTD1-FH crRNA: ccgcuuccucuaacacgugaThis PaperN/ACNTD1-FH HDR Donor: cctgggccacag\
cagcctgttccccacaaggcagccagagctctga\
ggactgctgccgctgccgcttcctctaacacg\
GACTACAAAGACGATGACGACAAGcttT\
ACCCATACGATGTTCCAGATTACGCTt\
gagggtggctgacccgcactgccttgtcactgg\
acctctttccttgtttacttttatactcagggThis PaperN/ACNTD1-FH Sequencing Primer, Forward: gcgcacgagtgtttgtgcactThis PaperN/ACNTD1-FH Sequencing Primer, Reverse: ccagtgacaaggcagtgcgggtcagccThis PaperN/ACNTD1 Mutant crRNA: UAGUGACUUUCA\
GUUCGGAGThis PaperN/ACNTD1 Wildtype and Mutant Primer, Forward: CCAAGGTGTGGCAGAAGATTCThis PaperN/ACNTD1 Wildtype Primer, Reverse: ctgtcaattccaggccagccThis PaperN/ACNTD1 Mutant Primer, Reverse: AGCCCTTGGAGGAGCCCThis PaperN/A**Recombinant DNA**pGADT7 ADClontech630442pGBKT7 DNA-BDClontech630443pX330Addgene42230**Software and Algorithms**Adobe Creative CloudAdobe<https://www.adobe.com/uk/creativecloud.html>Fiji-ImageJ([@bib62])<https://imagej.nih.gov/ij/>GraphPad Prism 6.0GraphPad<https://www.graphpad.com>Image Lab 6.0Bio-Rad<https://www.bio-rad.com/en-us/product/image-lab-software?ID=KRE6P5E8Z>Zen 2.0Zeiss<https://www.zeiss.com/microscopy/int/products/microscope-software/zen.html>

Resource Availability {#sec4.2}
---------------------

### Lead Contact {#sec4.2.1}

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Paula Cohen (<paula.cohen@cornell.edu>)

### Materials Availability {#sec4.2.2}

Plasmids and mouse lines generated within this study are available upon request from the Lead Contact, Paula Cohen (<paula.cohen@cornell.edu>)

### Data and Code availability {#sec4.2.3}

This study did not generate any code. Mass spectrometry dataset generated in this study is found within [Table S1](#mmc2){ref-type="supplementary-material"}.

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Mouse strains {#sec4.3.1}

All mouse alleles were maintained on a C57BL6/J background, with at least six successive backcrosses. CRISPR/Cas9 genome edited mice were created initially on a FVB x C57B6 background before undergoing backcrossing. In all cases, analysis was performed on adult male mice between the ages of 10 and 14 weeks. All mice were maintained under strictly defined conditions of constant temperature and light:day cycles, with food and water *ad libitum.* Animal handling and procedures were performed following approval by the Cornell Institutional Animal Care and Use Committee, under protocol 2004-0063.

### Transgenic mice generation {#sec4.3.2}

*Cntd1-FLAG-HA:* CRISPR/Cas9 was used to insert the FLAG-HA epitope at the C terminus of the *Cntd1* locus*.* The RNA guide was generated by cloning the *Cntd1* specific sequence (GCCGCTTCCTCTAACACGTGA) in between the *BbsI* restriction sites of pX330, courtesy of Feng Zhang (Addgene \#42230). Once integrated, the region including the gRNA scaffold was PCR amplified to include the T7 promoter. The PCR fragment was used to in an *in vitro* transcription reaction using the Ambion MEGAshortscript T7 Transcription Kit (AM1354). Single-stranded DNA homology donor containing 78 nucleotides of homology upstream of the guide sequence, FLAG and HA epitopes separated by a leucine (generating a HindIII restriction site) and 66 nucleotides of homology downstream of the *Cntd1* stop codon was generated by IDT. gRNA, DNA donor and Cas9 mRNA was injected into 146 C57BL/6J x FVB F1 zygotes. 119 two-cell embryos were surgically implanted in 5 female recipients leading to the birth of 46 founder mice. PCR screening identified 7 founders with DNA integrated at the locus, 3 of which were the correct size. Sequencing revealed one founder mouse having the tags integrated in the correct frame. The founder mouse was backcrossed with C57BL/6J for four generations before being used for experiments described.

### Cntd1 null allele {#sec4.3.3}

CRISPR/Cas9 was used to generate a DNA double-strand break at the *Cntd1* locus and founder mice were screened for non-homologous end joining events generating a frameshift mutation. The gRNA was generated using long PCR primers incorporating the T7 promoter, targeting sequence and Cas9 scaffold followed by PCR and *in vitro* transcription (see above). Founders were screened for mutations by PCR of the *Cntd1* locus followed by sequencing. One founder carried an incorporation of 324 nucleotides of chromosome 12 at the targeted locus leading to disruption of the *Cntd1*open reading frame.

### Yeast strain {#sec4.3.4}

Y2H Gold yeast strain (detailed in [Key Resources Table](#sec4.1){ref-type="sec"}) was used for yeast two-hybrid experiments and protein expression.

Method Details {#sec4.4}
--------------

### Plasmid construction {#sec4.4.1}

#### Yeast two-hybrid {#sec4.4.1.1}

Testis cDNA was generated from Trizol extracted RNA using the Invitrogen SuperScript® III First-Strand Synthesis System. CDKs 1, 2, 4, 5 and 6 were PCR amplified to include *NdeI* and BamHI restriction sites upstream and downstream respectively. The CDKs were cloned into Clontech yeast two-hybrid prey vector, pGADT7, using the Roche Rapid DNA Dephos & Ligation Kit. Annotated full-length CNTD1 and CNTD1 short-form sequences were PCR amplified to include *NcoI* and BamHI restriction sites upstream and downstream respectively. The CNTD1 sequences were cloned into the Clontech yeast two-hybrid bait vector pGBKT7.

#### CNTD1 expression constructs {#sec4.4.1.2}

The yeast CEN/ARS region from pRS414 was PCR amplified, introducing restriction sites *SpeI* upstream and *EcoRV* downstream. This fragment was cloned into pFA6a-HphMX. The promoter of ADH1 from pGADT7 along with FLAG-HA epitope tagged CNTD1 full-length and short-forms from mouse testis cDNA was PCR amplified and cloned into the previously constructed vector using Gibson Assembly.

### Cntd1 Orthology Sequence Alignment {#sec4.4.2}

Sequence alignments carried out using Clustal Omega. NCBI database IDs for annotated isoform sequences are as follows: *Mus musculus* (mouse), Iso1: NP_080838.1, Iso2: EDL01034.1; *Homo sapiens* (human), Iso1: NP_775749.2, IsoX2: XP_006721753.1, IsoX1: XP_005257100.2, Iso2: NP_001317151.1; Pan troglodytes (chimpanzee), IsoX1: XP_009430406, IsoX3, XP_016787256.1, IsoX2: XP_016787255.1, IsoX4: XP_024206054.1; Phascolarctos cinereus (koala), IsoX1: XP_020828270.1, IsoX2: XP_020828271.1, IsoX3: XP_020828272.1, IsoX4: XP_020828273.1; Canis familiaris (dog), IsoX2: XP_022278673.1, IsoX4: XP_022278675.1; Castor canadensis (American beaver), IsoX1: XP_020020731.1, IsoX2: XP_020020732.1.

### Yeast two-hybrid assay {#sec4.4.3}

The yeast two-hybrid assay was performed as described by the manufacturer, Clontech. Briefly, combinations of bait and prey plasmids were transformed into the yeast two-hybrid reporter strain Y2HGold and plated onto --LEU --TRP selection plates. Positive colonies were re-streaked and tested for plasmids using PCR. Single colonies were inoculated into --LEU --TRP media and grown overnight. Colonies were normalized to an OD600 or 1.0 and four, 10-fold dilutions made. 10μl drops were placed on selection plates and quadruple dropout plates, which were incubated at 30°C for 3 days.

### Chromosome analysis and immunofluorescence {#sec4.4.4}

Chromosome spreads were made as previously described in [@bib27]). Briefly, decapsulated testis tubules were incubated in hypertonic elution buffer (30 mM Tris pH7.2, 50 mM sucrose, 17 mM trisodium dehydrate, 5 mM EDTA, 0.5 mM DTT, 0.1 mM PMSF, pH8.2-8.4) for one hour. Small sections of testis tubule were dissected in 100mM sucrose and spread onto 1% Paraformaldehyde, 0.15% Triton X coated slides and incubated in a humid chamber for 2.5hrs at room temperature. Slides were dried for 30minutes, washed in 1x PBS, 0.4% Photoflo (Kodak 1464510) and either stored at −80°C or stained. For staining, slides were washed in 1xPBS, 0.4% Photoflo for 10 minutes, followed by a 10 minute wash in 1x PBS, 0.1% Triton X and finally a 10 minute wash in 10% antibody dilution buffer (3% BSA, 10% Goat Serum, 0.0125% Triton X, 1 x PBS) 1x PBS. Antibodies used in this study are described in [Table S1](#mmc2){ref-type="supplementary-material"}. Primary antibodies were diluted in 100% antibody dilution buffer, placed as a bubble on parafilm within a humid chamber, and the surface of the slide spread on the parafilm allowing the antibody to spread across the surface of the slide. Slides were incubated at 4°C overnight. Slides were washed in 1xPBS, 0.4% Photoflo for 10 minutes, followed by a 10 minute wash in 1x PBS, 0.1% Triton X and finally a 10 minute wash in 10% antibody dilution buffer. Secondary antibodies were diluted as the primary antibodies and spread in a similar fashion. Slides were incubated at 37°C for one hour. Slides were washed in 1xPBS, 0.4% Photoflo for 10 minutes, three times. Finally slides were left to dry, mounted using DAPI/antifade mix and either imaged or stored at 4°C for later imaging. Slides were imaged on a Zeiss Axiophot with Zen 2.0 software.

### Histology and immunofluorescence {#sec4.4.5}

Adult testes were dissected and incubated in either 10% neutral buffered formalin (for IHC) or Bouin's fixative (for hematoxylin and eosin \[H&E\] staining) for 8hrs to overnight. Fixed testis was then washed 4 x in 70% ethanol, embed in paraffin and 5 μM sections mounted on slides. For H&E staining, slides were rehydrated in safeclear followed by decreasing amounts of ethanol. Slides were then stained with hematoxylin followed by eosin then gradually dehydrated by incubation in increasing concentrations of ethanol. Finally, slides were mounted using permount and imaged on an Aperio Scanscope.

For immunofluorescence, slides were rehydrated as previously mentioned and then boiled in sodium citrate buffer (10mM Sodium Citrate, 0.05% Tween 20, pH 6.0) for 20 minutes. Following subsequent cooling, slides were blocked in blocking buffer (1 x PBST, 1% BSA, 3% Goat Serum) for an hour and primary antibody dilutions incubated on the sections overnight at 4°C. Slides were then washed, and incubated with fluorescence-conjugated secondary antibodies for one hour at 37°C, washed and then mounted using a DAPI/Antifade mix. Slides were imaged on a Zeiss Axiophot with Zen 2.0 software. Antibodies used in this study are described in the [Key Resources Table](#sec4.1){ref-type="sec"}.

Immunohistochemical staining of testis sections was similar to that described for immunofluorescent staining, except for the use of secondary antibodies conjugated to horseradish peroxidase (HRP; Jackson Immunochemicals). HRP detection was achieved using the Pierce DAB substrate Kit (ThermoFisher Scientific) according to the manufacturers detailed protocol.

### Sperm counts {#sec4.4.6}

Caudal epididymides of adult mice was transferred and dissected into sperm count media (4% BSA in 1 x PBS). Sample was incubated at 30°C for 30 minutes allowing sperm to swim out into the media. 1:10 dilutions were made in 10% neutral buffered formalin and stored at 4°C until counting on a haemocytometer.

### Spermatocyte diakinesis spread preparations {#sec4.4.7}

Spread diakinesis preparations were made as described in [@bib27]). Briefly, testis cells were liberated by manual dissection of tubules in 0.5% KCl. Multiple mixing and slow centrifugation followed by fixation in 30% methanol: 10% acetic acid: 0.05% chloroform. Cells were finally fixed in 30% methanol: 10% acetic acid and then pipette onto heated slides. Finally slides were stained in using Giemsa and imaged. Slides were imaged on a Zeiss Axiophot with Zen 2.0 software.

### Gravitational cell separation (STA-PUT) {#sec4.4.8}

Cells were separated using a protocol. The number of adult mice (8-12 weeks, age matched) used in each STA-PUT are as follows: [Figures 3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"} and [S5](#mmc1){ref-type="supplementary-material"}: 8 mice of the respective genotypes, [Figure 5](#fig5){ref-type="fig"}: 12 mice. Testis extracts were dissected into approximately 30 mL of 1 x Krebs buffer (Sigma K3753) supplemented with amino acids (GIBCO 11130-051, Sigma M7145) and glutaMAX (GIBCO 35050-061) in a Petri dish lid. Extract was incubated in a shaking water bath at 34°C, 150rpm in 10 mL of 2 mg/ml Collagenase (Sigma C5138) in 1 x Krebs for 15 minutes. Following three rounds of centrifugation and washing in 20 mL 1 x Krebs, the testis extract was re-suspended in 20 mL of 2.5mg/ml Trypsin (Sigma T0303), 200μg/ml DNase (Sigma DN25) in 1 x Krebs and incubated in a shaking water bath at 34°C, 150rpm for 15 minutes. Extract was then centrifuged and washed three times in 20 mL 1 x Krebs, followed by re-suspension in 20 mL 0.5% BSA (Sigma A7906). Extract was then loaded into the STA-PUT apparatus along with 275 mL 4% BSA in 1 x Krebs, 275 mL 2% BSA in 1 x Krebs and 100 mL 0.5% BSA in 1 x Krebs. Following loading of the BSA into the separating chamber along with the extract, the sample was allowed to sediment for 2 hr. Following sedimentation, cell fractions of 13 mL were collected, centrifuged at 2,000rpm for 5 minutes and washed in 200 μl 1 x PBS. For immunofluorescence analysis of cell types 5 μl of each fraction was re-suspended in 50mM sucrose and incubated at room temperature for 20 minutes. 30μl drops of 1% Paraformaldehyde (EMS 19200) were placed on each well of an 8 well slide and the 50mM sucrose cell mix were added to each well. Slides were incubated in a humid chamber overnight, followed by drying, washing and staining against proteins defining stages of prophase I, in our case SYCP3 and γH2AX. The remaining extract was centrifuged at 2,000 rpm for 5 minutes and re-suspended in 1 x PBS Lysis buffer (1 x PBS, 0.01% NP-40, 5% Glycerol, 150mM NaCl, 1 x Roche cOmplete), sonicated and stored at −20°C for downstream applications.

### Protein extraction {#sec4.4.9}

Decapsulated testis extract was re-suspended into 1 x PBS Lysis buffer (1 x PBS, 0.01% NP-40, 5% Glycerol, 150mM NaCl, 1 x Roche cOmplete) and sonicated for 20 s at 22% amplitude in cycles of 0.4 s on and 0.2 s off.

### SDS-PAGE and Western Blotting {#sec4.4.10}

Protein samples were separated by SDS-PAGE on gels varying in percentage from 6%--14% and transferred to methanol activated PVDF membranes using a Biorad Mini Trans-Blot Cell. Membranes were incubated in 5% BSA, 1 x TBST for 30minutes to 2 hours at room temperature while rotating at 60rpm. Membranes were incubated overnight in primary antibodies in 1 x TBST. Membranes were washed three times in 1 x TBST and subsequently incubated for one hour in secondary antibodies in 1 x TBST. Finally membranes were washed three times in 1 x TBST, developed using the ECL reagent and imaged using a Biorad ChemiDoc imager. Antibodies used in this study are described in The [Key Resources Table](#sec4.1){ref-type="sec"}.

### Colloidal Coomassie Staining {#sec4.4.11}

Protein extracts separated on SDS-PAGE gels were fixed in 40% methanol, 10% acetic acid for 30 minutes. Gels were stained using the Invitrogen Colloidal Coomassie staining kit (LC6025) in 20% methanol, 20% stainer A, 5% stainer B and incubated at room temperature overnight while slowly rocking. Gels were subsequently washed in double distilled water and imaged.

### Image acquisition {#sec4.4.12}

Imaging was performed using a Zeiss Axiophot Z1 microscope attached to a cooled charge-coupled device (CCD) Black and White Camera (Zeiss McM). Images were captured and pseudo-colored using ZEN 2 software (Carl Zeiss AG, Oberkochen. Germany). Higher resolution images were acquired using an ELYRA 3D-Structured Illumination Super resolution Microscopy (3D-SIM) from Carl Zeiss with ZEN Black software (Carl Zeiss AG, Oberkochen. Germany). Images are shown as maximum intensity projections of z stack images. To reconstruct high-resolution images, raw images were computationally processed by ZEN Black. Channel alignment was used to correct for chromatic shift. The brightness and contrast of images were adjusted using ImageJ (National Institutes of Health, USA).

### Mass spectrometry and protein identification {#sec4.4.13}

Mass spectrometry was performed in the Cornell University Proteomics and Mass Spectrometry facility. The nanoLC-MS/MS analysis was carried out using an Orbitrap Fusion (Thermo-Fisher Scientific, San Jose, CA) mass spectrometer equipped with a nanospray Flex Ion Source using high energy collision dissociation (HCD) and coupled with the UltiMate3000 RSLCnano (Dionex, Sunnyvale, CA). Each reconstituted sample was injected onto a PepMap C-18 RP nano trap column (3 μm, 100 μm × 20 mm, Dionex) with nanoViper Fittings at 20 μL/min flow rate for on-line desalting and then separated on a PepMap C-18 RP nano column (3 μm, 75 μm x 25 cm), and eluted in a 120 min gradient of 5% to 35% acetonitrile (ACN) in 0.1% formic acid at 300 nL/min. The instrument was operated in data-dependent acquisition (DDA) mode using FT mass analyzer for one survey MS scan for selecting precursor ions followed by 3 s "Top Speed" data-dependent HCD-MS/MS scans in Orbitrap analyzer for precursor peptides with 2-7 charged ions above a threshold ion count of 10,000 with normalized collision energy of 38.5%. For label-free protein analysis, one MS survey scan was followed by 3 s "Top Speed" data-dependent CID ion trap MS/MS scans with normalized collision energy of 30%. Dynamic exclusion parameters were set at 1 within 45 s exclusion duration with ± 10 *ppm* exclusion mass width. All data are acquired under Xcalibur 3.0 operation software and Orbitrap Fusion Tune 2.0 (Thermo-Fisher Scientific).

All MS and MS/MS raw spectra from each experiment were processed and searched using the Sequest HT search engine within the Proteome Discoverer 2.2 (PD2.2, Thermo). The default search settings used for relative protein quantitation and protein identification in PD2.2 searching software were: two mis-cleavage for full trypsin with fixed carbamidomethyl modification of cysteine and oxidation of methionine and demaidation of asparagine and glutamine and acetylation on N-terminal of protein were used as variable modifications. Identified peptides were filtered for maximum 1% false discovery rate (FDR) using the Percolator algorithm in PD 2.2. The relative label free quantification method within Proteome Discoverer 2.2 software was used to calculate the protein abundances. The intensity values of peptides, which were summed from the intensities values of the number of peptide spectrum matches (PSMs), were summed to represent the abundance of the proteins. Protein ratios are calculated based on pairwise ratio, where the median of all possible pairwise ratios calculated between replicates of all connected peptides.

### Short-term testis drug culture {#sec4.4.14}

Cultures were performed as described elsewhere ([@bib12]; [@bib68]), with some modifications. Testis extracts were dissected into 1 x PBS and incubated in a shaking water bath at 34°C, 150rpm in 2 mg/ml Collagenase (Sigma C5138) in 1 x PBS for 15 minutes. Following multiple rounds of centrifugation and washing in 1 x PBS, the testis extract was re-suspended in 2.5 mg/ml Trypsin (Sigma T0303), 200 μg/ml DNase (Sigma DN25) in 1 x PBS and incubated in a shaking water bath at 34°C, 150rpm for 15 minutes. Extract was then centrifuged and washed five times in 4 mL spermatocyte culture medium (SCM) (GIBCO DMEM without red phenol (21063-029), fetal calf serum (GIBCO 10082139), penicillin-streptomycin 1003 (GIBCO 15140-122); lactic acid (Sigma L13750, NaHCO3 9s8761) and sodium pyruvate 1003 (Sigma 11360-070). Cells were re-suspended in 600μl of SCM and placed in 12-well treated culture dishes (Corning \#3513). Adavosertib (MedChemExpress HY-10993) was diluted in 10% DMSO and added at 0.25, 0.5, 1, 2, 5 and 10 μg/ml. Nocodazole (Sigma SML1665-1ML) was diluted in 10% DMSO and added at 1, 5, 10, 20, 50 and 80 μg/ml. Cultures were incubated at 37°C for 6 hours followed by protein extraction.

Quantification and Statistical Analyses {#sec4.5}
---------------------------------------

Statistical analyses were performed using GraphPad Prism version 6.00 for Macintosh and Microsoft Excel. Signal intensity of prophase I staged cells from testis tubules ([Figure S7](#mmc1){ref-type="supplementary-material"}) was performed by outlining a minimum of 6 cells per stage and calculating the average intensity of each channel using ImageJ. Specific analyses are described within the text and the corresponding figures. Mean values are all presented ± standard deviation (s.d.) and alpha value was established at 0.05. All statistical analyses performed using two-sided tests.
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